Background: This prospective multicentric phase II study aimed to confirm the results of the C5R protocol of highdose methotrexate (MTX)-based chemotherapy (CT) for immunocompetent primary central nervous system lymphoma.
induce 35%-87% CR, with 32%-50% 5-year OS [3] [4] [5] [6] [7] [8] [9] [10] [11] . A pilot study conducted at the Centre Léon Bérard (Lyon, France) from 1984 to 1993 tested the C5R protocol derived from CT regimens used for pediatric Burkitt lymphomas: four polychemotherapy courses with HD-MTX and cytarabine, followed by brain RT [12] . The study reported 56% CR and 56% 5-year OS, but induced high toxicity in patients older than 60 years.
The LNHCP93 phase II study investigated the feasibility of the C5R regimen in the multicentric setting of the Groupe d'Etude des Lymphomes de l'Adulte and the reproducibility of results obtained in monocentric series. Patients younger than 60 years received the full C5R regimen while older patients received adapted doses. We report the long-term results of this prospective multicentric phase II study after a median followup of 83 months. patients and methods
eligibility criteria
Patients older than 18 years with unknown cause of immunodepression and newly diagnosed PCNSL were eligible. All histological subtypes were allowed. Diagnosis was obtained by histological biopsy or cytological analysis of the cerebrospinal fluid (CSF). All patients had measurable disease at diagnosis. Patients with isolated primary ocular or leptomeningeal lymphoma, systemic lymphoma, congenital or acquired immunodeficiency, inadequate renal and hepatic functions, cardiac contraindication to the use of anthracyclines, a history of mental disorder and psychiatric contraindication to corticosteroids, or a history of cancer were excluded. The protocol was approved by the local ethics committee. All patients provided written informed consent.
clinical staging
Patients underwent thorax, abdomen, and pelvis computed-tomography scans; bone marrow puncture; lumbar puncture with CSF cytology; and routine laboratory evaluation of bone marrow, liver, and renal functions. Patients treated by anthracyclines underwent cardiac ultrasound examination. All patients had cranial neuroimaging at diagnosis, preferably with contrast-enhanced magnetic resonance imaging (MRI). 
study group and treatment protocol

statistical analysis
The primary end point of this study was OS. The number of subjects in each group was calculated in order to obtain survival estimates at 5 years with 10% precision and 95% confidence interval. Expected rates were 40% for group 1 (65 patients to be included), 30% for group 2 (57 patients), and 10% for group 3 (25 patients). In April 2002, the study was stopped for toxicity in group 2, with a number of toxic deaths during CT above the limit set by the protocol. Because of slow accrual after 7 years, it was decided to stop inclusions in the two other arms at the same date. Survival was calculated from the beginning treatment to death from any cause or to last follow-up for living patients. Last evaluation was carried out on 22 January 2008.
Secondary end points were tumor response to treatment, progression-free survival (PFS), and the frequency and severity of toxic effects. PFS was measured from the beginning of treatment to disease progression or death or censored at last follow-up. Survival estimates were calculated using KaplanMeier method and compared using log-rank test [14] .
results
patient characteristics
Ninety-nine patients were enrolled: 45 younger than 60 years (group 1), 36 aged between 61 and 70 years (group 2) and 18 older than 70 years (group 3). Patient characteristics are summarized in Table 2 . Median age was 63 years (range 20-82), 52% were males, 51% had a performance status (PS) of more than 1 according to Eastern Cooperative Oncology Group scale and 90% had isolated cerebral disease. Six (6%) patients had oculocerebral lymphoma, three (3%) had leptomeningeal involvement at diagnosis of PCNSL, and 58 (58%) had deep lesions. Diffuse large-cell lymphoma was the most common histology (82 patients, 83%).
response to therapy
Responses to initial treatment are summarized in Table 3 . Two patients from group 1 and one from group 2 were not assessable for response. After CT, 33 (33%) patients were in CR, 37 (37%) in PR, 3 (3%) in SD, and 6 (6%) had PD. Seventy-nine patients (53%), and 5 (28%) patients from groups 1, 2, and 3, respectively. Groups 1 and 2 presented significantly higher CR rates than group 3 (P = 0.04 and P = 0.007, respectively). Among the 36 assessable patients in PR after CT, 16 (44%) achieved a CR after RT. Two other patients from groups 1 and 2 were in CR after RT but their status after CT was not available. None of the patients in SD or in PD after CT achieved CR after RT.
acute toxicity
Seventeen patients (17%) died during CT: 4 (9%), 10 (27%), and 3 (17%) in groups 1, 2, and 3, respectively. In group 1, three patients died after a septic shock during febrile neutropenia and one died of pneumonia with endocarditis. In group 2, three patients died of a septic shock, one developed intracranial and pulmonary abscesses, one died of arrhythmia, two had acute renal failure, one had lethal abdominal bleeding with grade 4 thrombopenia in a context of Varicella-zoster virus infection, and two died of unknown cause. In group 3, one patient had a septic shock, one had a cardiac complication, and one died following global deterioration of PS. In total, nine patients died of infectious causes. Grade 4 neutropenia was observed in 84%, 90%, and 63% and grade 4 infection in 16%, 19%, and 6% of the patients in groups 1, 2, and 3, respectively.
survival With a median follow-up of 83 months, the median OS was 33 months (46, 16, and 15 months for groups 1, 2, and 3, respectively) with a 5-year OS rate of 34% ( Figure 1A) . OS rates at 5 years were 42%, 31%, and 17% for groups 1, 2, and 3, respectively ( Figure 2A) . OS was significantly better in group 1 than in groups 2 and 3 (42% versus 31% and 17%; P = 0.006 and P = 0.004, respectively). At last follow-up, 24 patients were alive: 16, 4, and 4 in groups 1, 2, and 3, respectively; 41 had died of lymphoma, 17 of toxicity, five of leukoencephalopathy, one of septic shock, one of cranial trauma, and 10 of unspecified causes. Thirty-one patients survived 60 months or longer: 18, 11, and 2 in groups 1, 2, and 3, respectively. Long-term survivors were younger than other patients (58 versus 64 years, P = 0.01) but other clinical characteristics were not different. They more frequently experienced a CR after CT (65% versus 19%, P < 10 24 ) and after RT (81% versus 35%, P < 10 24 ) and relapsed less frequently (42% versus 65%, P = 0.03). Six of the 13 long survivors who relapsed were treated with HD-CT + autologous stem-cell transplantation (ASCT) and four were still alive at the time of analysis. Twelve long-term survivors had leukoencephalopathy.
relapse Thirty-one patients (55%) relapsed after a CR; 8 (14%) and 15 (27%) progressed during treatment and after a PR or SD, respectively. The median PFS was 20 months (28, 16, and 7 months for groups 1, 2, and 3, respectively) and the 5-year PFS was 26% ( Figure 1B ): 31%, 28%, and 11% for groups 1, 2, and 3, respectively ( Figure 2B ). PFS was significantly better in group 1 than in group 3 (P = 0.02) but not significantly different between groups 1 and 2 (P = 0.12). The site of relapse was documented for 43 patients. Thirty-two relapsed in the brain: two with leptomeningal and one with ocular involvement. Five patients had a meningeal relapse without brain localization, but two of them also had an ocular or a spinal relapse. One patient had an isolated ocular relapse and five had extracerebral relapses: three in the cervical nodes and one in testicular and adrenal sites. Treatment at relapse was documented for 53 patients. Thirty-five received CT. Seven of them were treated with HD-CT and ASCT, with a 3-year OS after relapse of 60%. Two patients underwent RT. Supportive care was the sole treatment for 16 patients. The median OS after relapse was 4.4 months for the whole cohort of relapsed patients: 6.2 and 3.5 months for group 1 and groups 2-3, respectively (P = 0.07).
Eight patients relapsed 60 months after diagnosis or later (range 63-88). All were in CR after initial treatment and represented 26% of relapsed patients after initial CR. No difference in initial characteristics was observed between these patients and others. Treatment at relapse was documented for seven patients. One received CT but died after 4 months. Three were treated with HD-CT + ASCT: one was alive after a short follow-up of 1 month and the other two relapsed and died rapidly after 15 and 32 months, respectively. One patient treated by RT was lost of follow-up and the last two patients died rapidly after supportive care.
prognostic factors
In univariate analysis, PS was predictive of PFS (P = 0.04) and showed a trend toward predicting OS (P = 0.08). Gender, number of brain tumors or presence of deep lesions as defined by the International Extranodal Lymphoma Study Group (IELSG) score [15] were not predictive of PFS or OS. Unfortunately, lactate dehydrogenase and CSF-protein levels at original article Annals of Oncology diagnosis were not available, so the prognostic value of the IELSG score could not be evaluated in this cohort. Regarding correlations between OS and response to treatment, the 33 patients in CR after CT presented a median OS of 81 months with a 5-year OS rate of 63%. The 16 patients not achieving CR after CT but who obtained a CR after RT had a median OS of 20 months and a 5-year OS rate of 31%. The 19 patients in PR after RT had a median OS of 35 months and a 5-year OS of 28%. A trend for a better OS was observed for patients in CR before RT compared with others (P = 0.07) (Figure 3 ). neurotoxicity Thirteen (32%) of the 40 assessable patients in group 1 and 11 (32%) of the 34 assessable patients in groups 2-3 developed leukoencephalopathy. The median time to leukoencephalopathy was 29, 36, and 22 months for the whole cohort, group 1 and groups 2-3, respectively. In five patients, death was attributable to neurotoxicity. At the date of last follow-up, 9 of the 24 patients alive had developed clinical neurotoxicity.
discussion
The C5R protocol reported in 1995 achieved high response rates and encouraging survival results with a projected 5-year OS rate of 56% but was associated with excessive toxicity in patients older than 61 years [12] . The LNHCP93 trial tested this regimen at full doses in patients aged 18-60 years and at reduced doses in elderly patients. Results must be compared with those of other large multicentric studies testing similar combinations of methotrexate (MTX)-based CT and RT, often using different treatment strategies (Table 4) . It is, to our knowledge, the second largest multicentric series reported [5] .
As in other series, we observed an important rate of conversion to CR after RT [3] [4] [5] [6] [7] [8] [9] [10] [11] . The prognostic value of CR after CT was previously reported by Korfel et al. [16] ; the new information from our analysis is that OS seemed to be longer in patients in CR before RT than in those converting to CR after RT. For these latter patients, the option of salvage CT instead of RT should be discussed. The rate of deaths (24%) attributable to the treatment was unacceptable for patients aged 60-71 years. Toxicity was largely related to the hematotoxicity of the drugs, doxorubicin, and cyclophosphamide. We maintained these two drugs which are important for lymphoma treatment; however, because of their low distribution to the brain, we used them only during the initial phase when the blood-brain barrier is virtually more permeable [17] . Regarding their significant acute toxicity, these drugs should probably be avoided in elderly patients. For younger patients, the rate of deaths caused by treatment was close to the 7% reported in our monocentric experience [18] . The median PFS in our series was 20 months, which is comparable to values reported by De Angelis, O'Brien, and Omuro, but our patients were slightly older [5, 9, 10] . OS rates at 5 years were close to those reported by De Angelis, Omuro, and O'Brien and slightly lower than those of Bessel and Gavrilovic [5, 7, 9, 10, 19] . After a long follow-up, we observed 8% of late relapses (>60 months), no plateau on the survival curve, and no specific prognostic factors for late relapse. Late relapses plead for a longer follow-up period, possibly 10 years, for patients with PCNSL, and strongly suggest the persistence of an occult clonal disease [20] .
In our study, 31% of patients achieved long-term survival; 42% of these were older than 60 years and 37% had poor PS at diagnosis. This confirmed the analysis of long-term survivors in Memorial Sloan-Kettering Cancer Center series emphasizing that poor PS and older age should not contraindicate effective treatment in PCNSL [7] . Neurotoxicity was reported in 32% of our patients. These results should be taken with caution as no formal prospective neuropsychological evaluation was carried out and mild neurological deteriorations were probably underestimated. However, they support data published by Gavrilovic and Omuro who reported 30% and 29% of patients with leukoencephalopathy after a long follow-up [7, 10] .
Survival rates obtained in elderly patients were close to those of other series, with a median PFS and OS of 14 and 16 months, respectively, as compared with 11 and 22 months in De Angelis series and 16 and 24 months in Kiewe series [5, 8] . Our MTX dose (1.5 g/m 2 ) was lower than in other protocols. Ferreri et al. [21] have shown that a high area under the curve of MTX predicts outcome in PCNSL patients, thus arguing in favor of MTX doses ‡3000/m 2 per course. To reduce neurologic toxicity, several teams have proposed to postpone RT for patients older than 60 years in CR after CT. In their studies specifically scheduled for elderly patients, median PFS ranged from 6 to 10 months and median OS from 14 to 35 months, with low neurotoxicity [3, [22] [23] [24] [25] .
For our patients younger than 60 years, median PFS and OS were 28 and 46 months, respectively. OS results were similar to those of other large series (median 37-51 months) [5, 7, 8, 11] . However, median PFS duration was slightly shorter than in the RTOG 93-10 study (38.8 months for patients younger than 60 years) [5] . Our protocol was more toxic than other MTX-based CT and caution should be taken about the risk of severe infection during CT. The rate of neurotoxicity was also high in this category of patients, raising the question of avoiding RT in first line for younger patients. Based on the efficiency of HD-CT + ASCT at relapse [26] , some teams have proposed HD-CT + ASCT consolidation without RT [27] . In conclusion, this study shows that the C5R regimen achieves survival rates similar to those reported with other recent PCNSL protocols for patients aged less than 60 years, at the expense of important acute toxicity. For elderly patients, less toxic regimens combining effective doses of MTX, adapted doses of cytarabine, and new agents like mAbs should be preferred [28, 29] . This study shows that late relapses (>5 years) are frequent despite CR after initial treatment. Another important information from this study is that response to CT could influence patient outcome. Shah et al. [29] have shown that increasing the total number of MTX-based CT cycles could increase the rate of CR. The cumulative risk of neurotoxicity in long-term disease-free PCNSL survivors is high with the combination of CT and RT, thus encouraging the use of standardized neuropsychological tests in clinical practice and the study of the role of RT in PCNSL [30] . 
